Topical formulations containing ruxolitinib as a JAK inhibitor for dermatological applications. Utilized in hospitals, clinics, and pharmacies for managing inflammatory skin conditions. Pharmaceutical manufacturers supply to healthcare distributors and procurement teams under regulatory compliance for B2B medical supply chains.